SciELO - Scientific Electronic Library Online

 
vol.40 issue157Chemical study of fraction ethyl acetate in the fungus Ganoderma lucidum, grown in agro-industrial wasteAllelopathic activity evaluation of Copaifera pubiflora (Benth), crude extracts on the germination of Mimosa pudica (Linnaeus) author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la Academia Colombiana de Ciencias Exactas, Físicas y Naturales

Print version ISSN 0370-3908

Abstract

SIERRA, Ligia. Research strategies for the treatment of Alzheimer desease with antioxidant polyphenolic compounds. Rev. acad. colomb. cienc. exact. fis. nat. [online]. 2016, vol.40, n.157, pp.608-620. ISSN 0370-3908.  https://doi.org/10.18257/raccefyn.408.

This review includes a description of the proposed mechanisms to explain the development of Alzheimer's disease (AD) and strategies for treatment in the light of these mechanisms, with emphasis on the use of polyphenolic compounds as therapeutic agents. The effects of reactive oxygen species ROS and presence of metal redox in the development of AD and treatment strategies with a drug or active substance, based on antioxidant and chelating activity and in its potentiality through signaling pathways are analyzed. Given the importance of polyphenolic compounds as natural antioxidants for treating of AD, in special the flavonoids family, this review takes into account examples of this family, with emphasis on the catechin type flavonoid (-)-epigalocatechin-3-gallate (EGCG). Understanding of how polyphenols are involved at the cellular level (role of its chemical structure in the interaction with the cell and therefore its biological activity) is required in order to modulate the interaction and signaling pathways to achieve the desired neurotrophic effects. Effects in vitro often do not correspond to those in vivo. Differences in concentrations and study conditions make that chemical and biological activities of a drug vary. This may be due in part to the need for an adjustment in concentration and time between preclinical and clinical studies. Furthermore, efficient release methods should be investigated, particularly considering that a therapeutic agent for neurological diseases should cross the blood - brain - barrier (BBB). Nanotechnology based on controlled release systems of drugs may overcome these limitations.

Keywords : Alzheimer's disease; Amyloid-beta plaques; Tau tangles; Polyphenolic compounds; Signaling pathways; Controlled drug release.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License